In a separate research investigation, it was documented that cetuximab might have the capacity to enhance the effectiveness of afatinib or osimertinib in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.